CCM
BIO icon

Coldstream Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Coldstream Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-840
Closed -$255K – 1200
2025
Q4 		$255K Sell
840
-86
-9% -$26.8K ﹤0.01% 990
2025
Q3 		$260K Buy
+926
New +$252K ﹤0.01% 1005
2025
Q2 		– Sell
-642
Closed -$156K – 1389
2025
Q1 		$156K Sell
642
-220
-26% -$66.2K ﹤0.01% 1128
2024
Q4 		$283K Buy
862
+14
+2% +$4.75K 0.01% 850
2024
Q3 		$284K Buy
848
+20
+2% +$6.35K 0.01% 865
2024
Q2 		$226K Sell
828
-24
-3% -$6.98K 0.01% 891
2024
Q1 		$295K Sell
852
-288
-25% -$94.7K 0.01% 775
2023
Q4 		$368K Buy
1,140
+480
+73% +$150K 0.01% 628
2023
Q3 		$237K Sell
660
-36
-5% -$13.9K 0.01% 688
2023
Q2 		$264K Buy
696
+60
+9% +$24.4K 0.01% 672
2023
Q1 		$305K Sell
636
-4
-0.6% -$1.87K 0.01% 622
2022
Q4 		$269K Buy
+640
New +$258K 0.01% 652
2022
Q2 		$292K Buy
590
+156
+36% +$81.2K 0.01% 572
2022
Q1 		$244K Sell
434
-151
-26% -$91K 0.01% 661
2021
Q4 		$442K Buy
+585
New +$438K 0.01% 460
2020
Q3 		– Sell
-657
Closed -$296K – 310
2020
Q2 		$296K Sell
657
-35
-5% -$15.4K 0.03% 232
2020
Q1 		$242K Sell
692
-109
-14% -$40.1K 0.03% 230
2019
Q4 		$297K Buy
801
+3
+0.4% +$1.06K 0.02% 255
2019
Q3 		$265K Hold
798
– – 0.02% 268
2019
Q2 		$250K Buy
798
+25
+3% +$7.49K 0.02% 269
2019
Q1 		$237K Buy
+773
New +$209K 0.02% 268
2018
Q4 		– Sell
-858
Closed -$269K – 321
2018
Q3 		$269K Buy
+858
New +$266K 0.02% 283

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Coldstream Capital Management's BIO Position: Q1 2026 in Review

Coldstream Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2026, closing a stake of 840 shares — an estimated $255K sold.

Coldstream Capital Management first reported a position in BIO in Q3 2018 and held it in 22 quarters. The position peaked at $442K in Q4 2021. 395 funds tracked by Wall St. Rank hold BIO as of Q1 2026.

  • Coldstream Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2026 after selling out during the quarter.
  • Coldstream Capital Management sold 840 Bio-Rad Laboratories Class A shares in Q1 2026, an estimated $255K.
  • Coldstream Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and held it in 22 quarters.
  • Coldstream Capital Management's Bio-Rad Laboratories Class A position peaked at $442K in Q4 2021.
  • 395 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.